Not Yet RecruitingNCT07399301
High-Intensity Functional Training on Physical Performance and Mental Health in Elderly With Sarcopenia
Phase not reported · 60 planned enrolment
- Countries listed
- 1
- Registry update
- April 20, 2026
Registry Intervention View
sham
Trial registrations containing the exact intervention label sham.
Exact registry label · Not reported
14 linked registrations
No aliases or equivalent products have been inferred.
Topics connected by trial metadata
11 linked registrations report posted results
This is a registry availability fact, not a safety result, comparison, or conclusion.
Understand the safety boundary →Registered trials
TerminatedNCT04757636
OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)
PHASE3 · 998 planned enrolment
- Countries listed
- 30
- Registry update
- August 5, 2025
TerminatedNCT04757610
OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)
PHASE3 · 986 planned enrolment
- Countries listed
- 24
- Registry update
- July 22, 2025
CompletedNCT02686658
Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
PHASE2 · PHASE3 · 286 planned enrolment
- Countries listed
- 7
- Registry update
- June 10, 2025
CompletedNCT00447954
A Study of an Encapsulated Cell Technology (ECT) Implant for Patients With Atrophic Macular Degeneration
PHASE2 · 53 planned enrolment
- Countries listed
- 1
- Registry update
- March 28, 2025
CompletedNCT04200248
A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneration
PHASE2 · 94 planned enrolment
- Countries listed
- 1
- Registry update
- June 8, 2023
TerminatedNCT04684394
A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration
PHASE2 · 50 planned enrolment
- Countries listed
- 1
- Registry update
- October 31, 2022
CompletedNCT01527500
Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)
PHASE2 · 158 planned enrolment
- Countries listed
- 1
- Registry update
- January 5, 2021
CompletedNCT03626636
A Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate® (Alg-1001) As A Treatment For Non-Exudative Macular Degeneration
PHASE2 · 42 planned enrolment
- Countries listed
- 1
- Registry update
- July 8, 2020
TerminatedNCT02247479
A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
PHASE3 · 906 planned enrolment
- Countries listed
- 19
- Registry update
- June 26, 2019
TerminatedNCT02398500
Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration
PHASE1 · PHASE2 · 25 planned enrolment
- Countries listed
- 1
- Registry update
- June 5, 2019
CompletedNCT00511706
Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)
PHASE2 · 243 planned enrolment
- Countries listed
- 9
- Registry update
- April 25, 2019
TerminatedNCT02087085
A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration
PHASE2 · 310 planned enrolment
- Countries listed
- 6
- Registry update
- April 23, 2019
TerminatedNCT01122511
Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration
PHASE2 · 4 planned enrolment
- Countries listed
- 1
- Registry update
- September 5, 2012